Amgen’s 10th anniversary in Romania provided the Romanian team with a great opportunity to reflect on our heritage and achievements, as well as look toward the many opportunities on the horizon. Country Director Alina Culcea summarizes the team’s learnings and considers Amgen Romania’s ongoing commitment to provide patient access to our transformative medicines.
“Amgen came to Romania at a time when biological treatment was scarce for Romanian patients and efforts of the pharma industry were focused on increasing access to innovation. The Amgen portfolio and its steadily increasing presence in oncology, hematology and general medicine has shaped Amgen into a reliable and reputable partner for decision makers, doctors and patients.
“We are proud that Amgen was a pioneer of such efforts and that over the years, our management has been a constant presence on the boards of industry associations.”
In a difficult and unsteady environment, Amgen Romania also gained a reputation for its commitment to transparency and integrity – acknowledged by authorities, peer companies, employees and partners. This is reflected in the affiliate’s steady growth, reaching over 65 team members in 2020.
In its mission to make Romanian patients’ lives better, Amgen Romania continues to be a place where staff members can develop, collaborate, have fun and learn together. “The passion and energy of the team proves that nothing is impossible if we put all our energy behind our efforts, and we care for those around us, as well as the environment,” Culcea says proudly. In fact, during the past 10 years, the team has successfully completed many corporate social responsibility projects, making a difference for local communities; this includes refurbishing schools, creating playgrounds, and planting trees, to name a few.
“We are also most proud of the work and commitment of the Clinical Trials and Cybersecurity teams, which are based in Romania. Their work is invaluable to Amgen worldwide and we are pleased to benefit from their insights and presence,” she notes.
Looking to the next decade, Culcea confirms the team has an ambitious strategy. “While a significant number of Amgen products have received reimbursement, it is an ongoing challenge to make them available to patients. This is where we will focus now,” she states.
“To me, Amgen Romania is the place where the impossible becomes possible. Although we are a small affiliate, we lead the Romanian Association of International Medicines Manufacturers (ARPIM). We have a solid reputation in terms of integrity, transparency and honoring our commitments. And two years into being the Country Director for the Amgen Romania affiliate, I am confident that together, we can achieve anything we put our minds to.”
Big congratulations to the entire team on this milestone!